Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2
Yazarlar (8)
Prof. Dr. Mustafa Umut Somuncu Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Belma Kalaycı
Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Prof. Dr. Ahmet AVCI Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Tunahan Akgün
Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Hüseyin Karakurt
Ali Rıza Demir
Yalçın Avcı
Prof. Dr. Murat Can Zonguldak Bülent Ecevit Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(Uluslararası alan indekslerindeki dergilerde yayınlanan tam makale)
|
||
| Dergi Adı | Hormone Molecular Biology and Clinical Investigation | ||
| Dergi ISSN | 1868-1883 Wos Dergi Scopus Dergi | ||
| Makale Dili | İngilizce | Basım Tarihi | 02-2020 |
| Cilt / Sayı / Sayfa | 41 / 2 / – | DOI | 10.1515/hmbci-2019-0062 |
| Makale Linki | https://doi.org/10.1515/hmbci-2019-0062 | ||
| Özet |
| BackgroundThe increase in soluble suppression of tumorigenicity 2 (sST2) both in the diagnosis and prognosis of heart failure is well established; however, existing data regarding sST2 values as the prognostic marker after myocardial infarction (MI) are limited and have been conflicting. This study aimed to assess the clinical significance of sST2 in predicting 1-year adverse cardiovascular (CV) events in MI patients.Materials and methodsIn this prospective study, 380 MI patients were included. Participants were grouped into low sST2 (n = 264, mean age: 60.0 ± 12.1 years) and high sST2 groups (n = 116, mean age: 60.5 ± 11.6 years), and all study populations were followed up for major adverse cardiovascular events (MACE) which are composed of CV mortality, target vessel revascularization (TVR), non-fatal reinfarction, stroke and heart failure.ResultsDuring a 12-month follow-up, 68 (17.8%) patients had MACE … |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 20 |